VIA
MPLT

Virtus Investment Advisers’s MapLight Therapeutics MPLT Stock Holding History

Virtus Investment Advisers’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Buy
+11,791
New +$339K 0.1% 249

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's MPLT Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 11,791 shares worth $423K. The stake represents 0.1% of the portfolio and ranks #249 among its holdings.

100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Virtus Investment Advisers held 11,791 shares of MapLight Therapeutics worth $423K as of Q2 2026.
  • MapLight Therapeutics was a new Virtus Investment Advisers position in Q2 2026.
  • MapLight Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #249 holding.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.